MASLD coexisting with polycystic ovary syndrome (PCOS) increases cardiometabolic risk
Authors' conclusion
PCOS + MASLD in adolescents, but not PCOS alone, increases the likelihood of obesity, insulin resistance and an adverse cardiometabolic phenotype during adulthood.
Study context
- Population
- Community-based female adolescents in the Raine Study assessed for PCOS (age 14 years) and MASLD (age 17 years), followed to age 27 years148 assessed at 27 y
- Participants
- 199 adolescents
- Exposure
- PCOS + MASLD vs only PCOS, only MASLD or neither
- PCOS + MASLDn = 12
- PCOSn = 20
- Neithern = 142reference
- Outcome
- Future cardiometabolic adverse parameters
- Follow-up
- Age 27 years (after 10 years)
Methodological detailslongitudinal, community-based, Raine Study, retrospectively determined diagnoses
- Longitudinal
- Community-based
- Raine Study
- Retrospectively determined diagnoses
Main finding
As reported in the abstract
Cardiometabolic parameters in adulthood · age 27 years
- PCOS + MASLD in adolescence (10/148): more insulin resistant, higher serum remnant lipoprotein cholesterol and TG/HDL-C ratio vs only PCOS or MASLD or neither (P < .05 for all)
- PCOS without MASLD or obesity in adolescence did not predict future insulin resistance
Observational data: associations, not effects.
Further findings
Prevalence at age 17 years
- MASLD
- 37 (18.6%)
- PCOS
- 32 (16.1%)
- PCOS without MASLD
- 20 (10.1%)
- Neither
- 142 (71.4%)
- PCOS + MASLD among adolescents with PCOS
- 12/32 (37.5%)
Adolescent phenotype of PCOS + MASLD · age 17 years
- PCOS + MASLD associated with obesity, higher serum remnant lipoprotein cholesterol, free and total testosterone, lower SHBG vs only MASLD, PCOS or neither (P < .05 for all)
Original publication
MASLD coexisting with PCOS increases cardiometabolic risk. J Clin Endocrinol Metab. Published 13 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →